4th Quarter - Report

CALIFORNIA LIFE SCIENCES for CALIFORNIA LIFE SCIENCES

Firm
Client
Income
—
Expenses
$180,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

8 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Support reforms to enable Value Based Healthcare, including reforms to Anti-Kickback Statute & Stark Law. Oppose International Pricing Index/reference pricing in Medicare, including Most-Favored Nation (MFN) EO, and H.R. 3. Support ensuring patient access to/coverage of critical breakthrough products via Hospital Inpatient Prospective Payment System (IPPS) proposed and final rules, Hospital Outpatient Prospective Patient System (OPPS) and Ambulatory Surgical Center (ASC) Payment System proposed and final rules, Medicare Coverage of Innovative Technology (MCIT) pathway proposed rule, final rule implementation, and legislation. Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem. Oppose drug importation proposals. Oppose changes to Notice of Benefit and Payment Parameters (NBPP) final rule re cost-sharing assistance. Support capping Medicare beneficiary out of pocket costs. Support expanded access to telehealth. Support value-based purchasing provision, but oppose line extensions and co-pay assistance provisions of CMS Medicaid VBP proposed rule.

LobbyistCovered position, as disclosed
CHRISTOPHER CUNNINGHAM New —

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 3 (117th)

Taxation/Internal Revenue Code TAX

Support Research and Development and NOL tax incentives, Orphan Drug Tax Credits, repeal Research and Development tax amortization.

LobbyistCovered position, as disclosed
CHRISTOPHER CUNNINGHAM New —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medical/Disease Research/Clinical Labs MED

Support NIH research funding. Support implementation of 21st Century Cures Act. Support promulgation of TCET rule. Support alternatives to animal research.

LobbyistCovered position, as disclosed
CHRISTOPHER CUNNINGHAM New —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Copyright/Patent/Trademark CPT

Address concerns with provisions of patent litigation reform, including inter partes review. Support STRONGER Patents Act. Oppose "march-in" rights and "compulsory licensing" proposals. Support transferable exclusivity extensions to incentivize novel antibiotic Research and Development.

LobbyistCovered position, as disclosed
CHRISTOPHER CUNNINGHAM New —

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Trade (domestic/foreign) TRD

Oppose proposals to reduce data exclusivity. Oppose proposals to restrict data uses. Oppose WTO TRIPS waiver for COVID diagnostics and therapeutics. Support USTR resolution process with Mexico trade authority to allow biotech corn into Mexican market.

LobbyistCovered position, as disclosed
CHRISTOPHER CUNNINGHAM New —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Defense DEF

Oppose domestic manufacturing/procurement mandates in NDAA for pharmaceutical products, APIs, & medical devices.

LobbyistCovered position, as disclosed
CHRISTOPHER CUNNINGHAM New —

Contacted: HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

Labor/HHS/Ed Appropriations: Drug Pricing, FDA, NIH, biodefense/pandemic, CDC, science/math education, and strategic stockpile funding and preparation. Coronavirus funding and response. FDA Appropriations. PTO Appropriations. E-Labeling appropriations language. Drug Pricing proposals, Orphan Drug Tax Credit. Semiconductor/CHIPS funding. Oppose budget reconciliation with drug pricing.

LobbyistCovered position, as disclosed
CHRISTOPHER CUNNINGHAM New —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Support FDA user fee programs and review process consistency and predictability. Support FDA modernization practices. Support legislation proposing coverage for multicancer screening. Support FDA modernization efforts and vaccine awareness. Oppose domestic manufacturing/procurement mandates for pharmaceutical products, APIs, & medical devices. Support improvements to the Strategic National Stockpile for pandemic testing preparedness. Support public education campaign on pandemic preparedness. Support reauthorization of Rare Pediatric Disease Priority Review Voucher (RPD PRV) program. Oppose drug importation proposals. Support diversity in clinical trial policy. Support medical device change control plans legislation. Oppose drug pricing proposals that allow Medicare to directly negotiate prices. Support alternatives to animal testing in trials.

LobbyistCovered position, as disclosed
CHRISTOPHER CUNNINGHAM New —

Contacted: Natl Institutes of Health (NIH); Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.